Record-breaking sales of $24.8bn by 2021 predicted for Pfizer/BioNTech's vaccine

15 April 2021

Pfizer (NYSE: PFE) and BioNTech’s (Nasdaq: BNTX) Comirnaty (tozinameran) is forecast to have peak sales of $24.8 billion by 2021, which is only its second year on the market.

This is a 20% increase over Humira’s peak sales of $20.5 billion, suggesting that Comirnaty could be the next top drug by peak sales within only two years of its launch, says analytics company GlobalData.

“Humira has been the top drug by sales for nearly a decade, despite having been on the market for nearly 20 years and having lost its market exclusivity within the EU in 2018 and Japan in 2017,” noted GlobalData analyst for drugs database Quentin Horgan. “The fact that Pfizer/BioNTech is estimated to end this reign after only two years is unprecedented and shows the power of this drug’s high efficacy, its first-to-market status, the demand presented by ongoing vaccination programs and that Comirnaty is considered the gold standard for COVID-19 vaccines,” he said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK